PPIDT00235
Drug Information
| Name | Ganirelix |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB06785 |
| Type | small molecule |
| Indication | Ganirelix is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation for assisted reproduction techniques (ART).[L43040, L43045] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Subcutaneous |
0.25 MG/0.5ML
|
| Injection | Subcutaneous |
250 ug/0.5mL
|
| Injection, solution | Subcutaneous |
250 ug/0.5mL
|
| Injection, solution | Parenteral |
0.25 mg/0.5ml
|
| Solution | Parenteral |
0.250 mg
|
| Solution | Subcutaneous |
250 mcg / 0.5 mL
|
| Injection | Subcutaneous |
0.25 mg/0.5ml
|
| Solution | Subcutaneous |
0.25 mg
|
| Injection, solution | — |
0.25 MG/0.5ML
|
| Solution | Subcutaneous |
0.5 mg/1ml
|